Employement of supplement bioestimulin in oncohematologic patients

Authors

  • María Aloida Guerra Instituto de Investigaciones para la Industria Alimenticia
  • Tatiana Beldarraín-Iznaga Instituto de Investigaciones para la Industria Alimenticia
  • Aster Bruselas Instituto de Investigaciones para la Industria Alimenticia
  • Angela Miranda Instituto de Investigaciones para la Industria Alimenticia
  • Teresa Pedroso Hospital “Dr. Luís Díaz Soto”
  • Elba Barrero Instituto de Investigaciones para la Industria Alimenticia
  • Frank Rodríguez Instituto de Investigaciones para la Industria Alimenticia
  • José Gómez Hospital “Dr. Luís Díaz Soto”
  • Aliuska Venegas Hospital “Dr. Luís Díaz Soto”
  • Adrián Romero Hospital “Dr. Luís Díaz Soto”
  • Azalea Díaz Hospital “Dr. Luís Díaz Soto”
  • Zobeida Frometa Instituto de Investigaciones para la Industria Alimenticia
  • Carmen Casañas Instituto de Investigaciones para la Industria Alimenticia
  • Casamayor Laime Hospital “Dr. Luís Díaz Soto”
  • Norma Vergara Instituto de Investigaciones para la Industria Alimenticia
  • Cecilia Carrillo Instituto de Investigaciones para la Industria Alimenticia
  • Irina Montano Hospital “Dr. Luís Díaz Soto”
  • Zuleica Judith Rodríguez Hospital “Dr. Luís Díaz Soto”
  • Darlene Guedes Hospital “Dr. Luís Díaz Soto”

Keywords:

Bioestimulin, oncohematoligic patients, anaemia control

Abstract

To evaluate the effectiveness and the acceptance of nutritional supplement Bioestimulin in oncohematologics patients, two groups were studied; a first group of the oncology consultation and a second group of the hematology consultation, for a total of 92 patients. 15 g of Bioestimulin three times at days (45 g/d) were given to each patient of both groups. Hemoglobin analysis was carried out to all patients at the beginning of the study and the three months after the supplement administration to establish the comparison with the values of this complementary analysis. Also, seric iron evaluation in patients of hematology consultation was done. The acceptance of product was determinate using an interview in all patients. The treatment with 45 g/d of Bioestimulin supplement increased significantly the hemoglobin to the 90 days in all oncohematologic patients. The seric iron also increased significantly in the patients of the hematology consultation. This product was accepted by all patients. The treatment with the nutritional supplement Bioestimulin is effective for the prevention and control of the anaemia in oncohematologic patient.

Downloads

Published

2023-12-18

Issue

Section

Original articles

How to Cite

Employement of supplement bioestimulin in oncohematologic patients. (2023). Ciencia Y Tecnología De Alimentos, 23(3), 52-57. https://revcitecal.iiia.edu.cu/revista/index.php/RCTA/article/view/521

Similar Articles

1-10 of 60

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 > >>